

HAEMONETICS®

Table 1: Reconciliation of Total Fiscal 2026 U.S. Electrophysiology Growth by Procedure to Total Access Site Opportunity Growth for Vascular Closure

Procedures ⁵	Afib	VT	SVT/FL	LAAC	Total
Total Procedures (in thousands) ¹	389	21	90	185	685
YoY Growth ¹	13.6%	4.4%	2.2%	11.9%	11.2%
Average Access Sites per Procedure ^{2,3}	3.00	3.20	3.20	1.25	2.56⁶
Total Access Sites Opportunity (in thousands)⁴	1,166	66	288	231	1,751
YoY Growth	9.9%	4.4%	2.2%	11.9%	8.6%

1) Total electrophysiology procedures (in thousands) expected to be performed in the U.S. in Fiscal 2026. Procedures data and YoY Growth rates derived from DRG/Clarivate. 2) Average number of access sites created during the procedure requiring closure. 3) Independent third-party primary market research (survey) from Q1 of CY 2025 of ~60 US Electrophysiology doctors. 4) Total Access Site Opportunity (in thousands) is calculated as Total Procedures multiplied by Average Access Sites per Procedure. 5) Afib – Atrial Fibrillation ablation, VT – Ventricular Tachycardia ablation, SVT – Supra Ventricular Tachycardia, FL – Atrial Flutter 6) Weighted average of access sites per procedure based on expected market share percentages.

HAEMONETICS®


Table 2: Reconciliation of Total Fiscal 2026 U.S. Coronary & Peripheral Growth by Procedure to Total Access Site Opportunity Growth for Vascular Closure

Procedures ⁵	Coronary DX	PCI	PAD	TAVR	All Other	Total
Total Procedures (in thousands) ¹	1,660	782	612	130	508	3,692
YoY Growth ¹	1.6%	0.9%	1.7%	11.8%	1.9%	1.7%
Average Access Sites per Procedure ^{2,3}	1.00	1.00	1.00	1.00	1.00	1.00⁶
Total Access Sites Opportunity (in thousands)⁴	1,660	782	612	130	508	3,692
YoY Growth	1.6%	0.9%	1.7%	11.8%	1.9%	1.7%

1) Total coronary & peripheral procedures (in thousands) expected to be performed in the U.S. in Fiscal 2026. Procedures data and YoY Growth rates derived from DRG/Clarivate. 2) Average number of access sites created during the procedure requiring closure. 3) Independent third-party primary market research (survey) from Q3 of CY 2024 of ~60 US Interventional Cardiologists. 4) Total Access Site Opportunity (in thousands) is calculated as Total Procedures multiplied by Average Access Sites per Procedure. 5) Coronary DX – Coronary Diagnostic, PCI – Percutaneous Coronary Intervention, PAD – Peripheral Artery Disease Diagnostic and Intervention, TAVR – Trans Aortic Valve Replacement, “All Other” includes Ablation Electrophysiology Study, Venous Thromboembolism, Interventional Neurology, Atrial Septal Defect, Patent Foramen Ovale, Tricuspid Valve Repair, Heart Transplant Intervention and Fractional Flow Reserve. 6) Weighted average of access sites per procedure based on expected market share percentages.



Chart 1: Fiscal 2026 Total Addressable Market for Vascular Closure in the U.S.¹



1) Total electrophysiology (EP) and coronary & peripheral Total Addressable Markets (TAMs) calculated using procedures (in thousands) expected to be performed in the U.S. in Fiscal 2026 (data from DRG/Clarivate), multiplied by average number of access sites created during the procedure requiring closure (EP data from independent third-party primary market research (survey) from Q1 of CY 2025 of ~60 US EP doctors. Coronary & peripheral data from independent third-party primary market research (survey) from Q3 of CY 2024 of ~60 US Interventional Cardiologists), multiplied by average selling price per vascular closure device.